stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Return on assets
Haemonetics Corporation's return on assets over the twelve months to 30 September 2026 was 4.28%, up 0.3 percentage points from fiscal 2026 (4.02%). Over the past ten years it has ranged from −3.96% (fiscal 2016) to 7.22% (fiscal 2025); the current reading is higher than 50% of that period. That is above the Medical Devices industry median of −17.3% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2026 | 4.02% | (3.20) |
| FY2025 | 7.22% | 1.53 |
| FY2024 | 5.69% | (0.39) |
| FY2023 | 6.08% | 3.72 |
| FY2022 | 2.36% | (2.79) |
| FY2021 | 5.15% | (0.87) |
| FY2020 | 6.02% | 1.64 |
| FY2019 | 4.38% | 0.70 |
| FY2018 | 3.68% | 5.73 |
| FY2017 | −2.05% | 1.91 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | 9.99% |
| BIO Bio-Rad Laboratories, Inc. compare | 9.99% |
| LIVN LivaNova PLC compare | 7.44% |
| HAE Haemonetics Corporation | 4.28% |
| ITGR Integer Holdings Corporation compare | 3.05% |
| BRKR Bruker Corporation compare | −2.73% |
| IRTC iRhythm Holdings, Inc. compare | −3.70% |
| TXG 10x Genomics compare | −7.47% |
| AXGN AxoGen, Inc. compare | −8.33% |
| Medical Devices industry median | −17.3% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on HAE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement